MSB's product isn't homologous is it?
Homologous mean that you use the same type of cell to treat the same type of problem - so skin cells for skin cells, blood cells for blood cells - whereas MSB's products are Bone marrow stem cell derived.
I think this is targeted at regulating stem cell clinics that are already offering unregulated treatments rather than providing a pathway for new drug/treatment approval.
FDA announce new policy approach, page-78
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.015(1.29%) |
Mkt cap ! $1.347B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.20 | $1.15 | $4.551M | 3.886M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 98246 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 19079 | 2 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |